Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12203799 | 0.72 | MAPK1 (0.49) | MAPK1TSHRCYP2C9ALDH1A1SMN1; SMN2 | |
| SCHEMBL3197862 | 0.69 | ALDH1A1 (0.40) | TSHRCYP2C9ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL2805733 | 0.65 | TSHR (0.58) | MAPK1TSHRCYP2C9ALDH1A1SMN1; SMN2 | |
| SCHEMBL3966355 | 0.65 | SMN1; SMN2 (0.46) | MAPK1TSHRCYP2C9ALDH1A1SMN1; SMN2 | |
| SCHEMBL10535225 | 0.63 | MAPK1 (0.37) | MAPK1TSHRCYP2C9ALDH1A1SMN1; SMN2 | |
| SCHEMBL25121396 | 0.61 | MAPK1 (0.60) | MAPK1TSHRCYP2C9ALDH1A1SMN1; SMN2 | |
| SCHEMBL10533754 | 0.59 | CYP2C9 (0.41) | MAPK1TSHRCYP2C9ALDH1A1SMN1; SMN2 | |
| SCHEMBL15719821 | 0.58 | — | — | |
| SCHEMBL13292098 | 0.58 | TSHR (0.36) | MAPK1TSHRCYP2C9ALDH1A1SMN1; SMN2 | |
| SCHEMBL17995472 | 0.57 | TSHR (0.43) | MAPK1TSHRCYP2C9MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113330-A1 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113330-A1 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GPR180, GPR84 | MAPK1 3752/4885TSHR 812/4885CYP2C9 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.